Wednesday, November 19, 2025 11:50:53 PM
Great post from stocktwits .....Tompopcorn89
😍$NWBO 😍
NWBO Q2 ? Q3 Comparison: The REAL Takeaways (They’ve Dotted Every “i” & Crossed Every “t”)
Here’s what actually changed from Q2 to Q3 — and why it matters:
1. MAA Process Is Effectively DONE
Q2 was “we’re working on it.”
Q3 is “the process is finished and we’ll announce results when regulators are done.”
That’s the closest you’ll ever get to “approval is imminent” without saying it outright.
2. Advent Acquisition Finalized
Q2 = negotiating.
Q3 = definitive agreement signed, closing conditions met.
You don’t buy your contract manufacturer right before approval unless you expect to become a commercial company.
Huge tell.
3. UK Manufacturing (Sawston) Is in Full Commercial Prep
• Engineering finalized
• Procurement accelerated
• Major equipment acquired
• Avoided 10–12 month lead times
This is commercial scaling, not R&D.
Bullish
Nov 15, 2025 7:49 AM
😍$NWBO 😍
NWBO Q2 ? Q3 Comparison: The REAL Takeaways (They’ve Dotted Every “i” & Crossed Every “t”)
Here’s what actually changed from Q2 to Q3 — and why it matters:
1. MAA Process Is Effectively DONE
Q2 was “we’re working on it.”
Q3 is “the process is finished and we’ll announce results when regulators are done.”
That’s the closest you’ll ever get to “approval is imminent” without saying it outright.
2. Advent Acquisition Finalized
Q2 = negotiating.
Q3 = definitive agreement signed, closing conditions met.
You don’t buy your contract manufacturer right before approval unless you expect to become a commercial company.
Huge tell.
3. UK Manufacturing (Sawston) Is in Full Commercial Prep
• Engineering finalized
• Procurement accelerated
• Major equipment acquired
• Avoided 10–12 month lead times
This is commercial scaling, not R&D.
Bullish
Nov 15, 2025 7:49 AM
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
